Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 6.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,721 shares of the company's stock after selling 12,401 shares during the period. Allspring Global Investments Holdings LLC owned about 0.44% of Tarsus Pharmaceuticals worth $8,667,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Northern Trust Corp increased its stake in Tarsus Pharmaceuticals by 12.6% in the 4th quarter. Northern Trust Corp now owns 357,616 shares of the company's stock valued at $19,801,000 after purchasing an additional 40,061 shares in the last quarter. GAMMA Investing LLC increased its stake in Tarsus Pharmaceuticals by 36,430.6% in the 1st quarter. GAMMA Investing LLC now owns 13,151 shares of the company's stock valued at $676,000 after purchasing an additional 13,115 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $1,107,000. Ameriprise Financial Inc. increased its stake in Tarsus Pharmaceuticals by 21.2% in the 4th quarter. Ameriprise Financial Inc. now owns 47,685 shares of the company's stock valued at $2,640,000 after purchasing an additional 8,336 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth $227,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on TARS. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target for the company in a research report on Tuesday, May 27th. Guggenheim raised their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer began coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 price target for the company. Finally, The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $66.67.

Tarsus Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:TARS traded down $0.24 during midday trading on Tuesday, reaching $39.69. The company's stock had a trading volume of 557,710 shares, compared to its average volume of 685,678. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -14.54 and a beta of 0.80. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The business has a 50 day moving average price of $42.92 and a 200 day moving average price of $47.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. Research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.